| Revenue Growth | MedSurge -2.8% organic; Dental -7.4% organic; HIS +4.4% organic growth. |
|---|---|
| Mgmt Confidence | High confidence in 2027 margin expansion despite 120 bps tariff headwind. |
| Demand Visibility | Normalized growth at 4%; high retention in HIS revenue cycle management. |
| Order Book | Reversal of $125 million ERP-related advanced orders impacted Q3 results. |
| Margin Trends | Gross margin 57.1%; operating margin 19.9% (22.3% normalized excluding ERP). |
| Op. Leverage | Transform for Future program delivered $160 million of $500 million target. |
| Pricing Power | Pricing remained stable within expected range of plus or minus 1%. |
| Vol vs Price | Volume remained the primary driver of underlying organic growth. |
| Segment Growth | Asera grew 35%; HIS revenue cycle management continues strong performance. |
| Capex & Debt | Net debt $4.6 billion; $50 million share repurchases; Asera integration on-track. |
| Regulatory | Received 510K clearance for Restrata combined use with VAC therapy. |
| Commentary | Emphasized 'say-do equation' and 90% completion of risky structural separation work. |
| New Launches | VAC Peel and Place; ClinProClear; Filtech EasyMatch; Clarity composite veneers. |
Growth
Organic sales fell 2.8% due to ERP timing; normalized growth was 4%. HIS grew 4.4%.
Outlook
Raised 2026 EPS to $7.20-$7.30; targeting 23-25% operating margins by 2028.
Risks
HIS separation causes 400 bps margin dilution; management was vague on specific EPS dilution impacts.
The company's earnings call, NYSE: SOLV, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Solventum Corp: key numbers
- Share price
- $88.65Close, Nov 16
- Market cap
- $15B
- Shares outstanding
- 169.74MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Solventum Corp
All →Solventum Q3 2026 Results: Net Loss of $12M
Solventum reported a net loss of $12 million for the third quarter of 2026, down from a net income of $1.27 billion in the prior year period, which was significantly impacted by a $1.5 billion gain on a business sale. Total net sales decreased to $1.95 billion from $2.10 billion year-over-year, while the company continued its share repurchase program, spending $403 million on treasury stock during the first nine months of the year.
- Key figure
- Net loss $12M
Solventum Financial Results
Solventum reported Q3 2026 financial results with net sales of $1.9 billion, a 7.0% decrease primarily due to the impact of advance orders placed in the prior quarter. Despite the sales decline, the company raised its full-year adjusted EPS guidance and reported that its separation from 3M is now more than 90% complete.
- Term
- Q3 2026
“Solventum delivered third quarter results ahead of our expectations, with every segment contributing, even as we completed our largest ERP cutover; we expect to be near the top end of our full-year organic sales growth range, and are raising our full-year adjusted earnings per share outlook.”
Bryan Hanson, chief executive officer of Solventum
“With separation now more than 90% complete and our growth drivers gaining momentum, we are well positioned to accelerate sales growth and expand margins. We have differentiated innovation, a strong pipeline of new products and a significant opportunity to expand penetration of our existing brands with customers we already serve.”
Bryan Hanson, chief executive officer of Solventum